Physician profile
Veronica Rupel
NPI 1366200966
$1,870.46
in general payments reported to CMS, 2019-2025
22 companies · $1,445 in 2025
The $1,445 reported for 2025 was more than what 92% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $426 · 2025: $1,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,870.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $439.58 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $360.41 | 2024-2025 | |
| Lilly USA, LLC | $187.02 | 2024-2025 | Zepbound, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $139.89 | 2024-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $133.49 | 2024-2025 | |
| Novo Nordisk INC | $87.64 | 2024-2025 | Wegovy, Ozempic |
| Pfizer INC. | $67.01 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.03 | 2024-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $54.75 | 2025 | Auvelity |
| Sumitomo Pharma America, INC. | $43.69 | 2025 | Gemtesa |
| Exact Sciences Corporation | $41.99 | 2025 | The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $39.52 | 2024-2025 | Veozah |
| Paratek Pharmaceuticals, INC. | $33.18 | 2024-2025 | Nuzyra |
| Alnylam Pharmaceuticals INC. | $28.13 | 2024 | Onpattro |
| Corcept Therapeutics | $23.26 | 2025 | Korlym |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $21.48 | 2024-2025 | Voquezna |
| Grifols USA, LLC | $20.70 | 2025 | Prolastin-C Liquid |
| Verona Pharma, INC. | $18.52 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.33 | 2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $16.88 | 2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.80 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $14.16 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Rupel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.